406 results on '"Dangond, Fernando"'
Search Results
52. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis
53. Focal brain dysfunction in a 41-year old man with familial alternating hemiplegia
54. Supplementary_Materials – Supplemental material for Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
55. Human T-Lymphotropic Viruses (HTLVs)
56. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice
57. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells
58. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study
59. Additional file 6: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study
60. Additional file 1: of Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsingâ remitting multiple sclerosis at year 1
61. Supplementary Material, MSJ771875_supplementary_material – Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
62. Additional file 2: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study
63. Additional file 3: of Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsingâ remitting multiple sclerosis at year 1
64. Additional file 3: of Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study
65. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS
66. 056 Efficacy and safety of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study
67. 088 Cladribine tablets were associated with rapid onset of improvements in MRI outcomes in the ORACLE-MS trial
68. 090 The effect of cladribine tablets on delaying the time to conversion to clinically definite multiple sclerosis (MS) or McDonald MS is consistent across subgroups in the ORACLE-MS study
69. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
70. Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
71. Cladribine tablets were associated with rapid onset of improvements in MRI outcomes in the ORACLE-MS trial (P3.2-061)
72. Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomized, Placebo-Controlled, Phase 2 Study (S56.004)
73. The effect of cladribine tablets on delaying the time to conversion to CDMS or McDonald MS is consistent across subgroups in the ORACLE-MS study (P3.2-101)
74. Analyse primaire d’une étude de Phase 2 randomisée, contrôlée par placebo évaluant l’évobrutinib (M2951), un inhibiteur de la tyrosine kinase de Bruton, chez des patients atteints d’une forme récurrente de sclérose en plaques
75. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
76. WED 185 Clarity: mri outcomes in high disease activity relapsing ms
77. WED 182 Cladribine tablets effects on lymphocytes in ms patients
78. WED 184 Cladribine tablets in clarity patients with high disease activity ms
79. THUR 178 Infections during grade 3/4 lymphopenia with cladribine tablets
80. THUR 192 Yearly lymphopenia rates in cladribine tablets-treated rms patients
81. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis
82. 067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies
83. 039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets
84. 040 An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis
85. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
86. Integrated Safety Analysis of Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kg (P3.407)
87. Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell Subsets (P5.364)
88. Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370)
89. Résultats radiologiques obtenus avec cladribine comprimés dans des sous-groupes de patients atteints d’une forme active de sclérose en plaques récurrente dans l’étude CLARITY
90. Proportions de patients atteints d’une forme très active de SEP récurrente ne présentant aucun signe d’activité de la maladie en réponse au traitement par cladribine comprimés dans l’étude CLARITY
91. Taux de lymphopénie année par année chez des patients atteints d’une forme récurrente de la sclérose en plaques traités et retraités par cladribine comprimés à la dose de 3,5 mg/kg
92. Numération des cellules immunitaires innées chez les patients atteints de sclérose en plaques récurrente-rémittente (SEP-RR) traités par cladribine comprimés à la dose de 3,5 mg/kg dans les études CLARITY/CLARITY Extension
93. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
94. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study
95. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
96. Early MRI results and odds of attaining ‘no evidence of disease activity’ status in MS patients treated with interferon β-1a in the EVIDENCE study
97. Efficacy of Cladribine Tablets 3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study (P6.360)
98. Cladribine tablets in the ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS) (P6.349)
99. Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study (P6.351)
100. Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies (P6.353)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.